🔴High Risk (Highly Volatile, Potential for Pullback)
OMGA $Omega Therapeutics (OMGA.US)$ – Extreme turnover, high pump-and-dump risk.
WINT $Windtree Therapeutics (WINT.US)$ – Overheated, susceptible to sharp pullback.
FTEL $Fitell (FTEL.US)$ – Post-crash rebound, uncertain sustainability.
AVGR $Avinger (AVGR.US)$ – Weak momentum, high chance of sell-off.
🟡Moderate Risk (Significant Fluctuations, Caution Needed)
HEPA $Hepion Pharmaceuticals (HEPA.US)$ – High turnover, needs strong fol...

$OncoCyte (OCX.US)$
Oncocyte Prices $29.1 Million Equity Offering
Monday, 10th February at 8:30 am
• Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial Launch
• Strategic Partner Bio-Rad Invests, Boosts Support for Trial and Commercialization
IRVINE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investor...

$OncoCyte (OCX.US)$ Reuters· 1 min ago
OncoCyte Prices $29.1 Million Equity Offering! Proceeds Expected to Fund Transplant Assay Through FDA Ivd Clearance and Commercial Launch

$OncoCyte (OCX.US)$ Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study
4 MINUTES AGO, 4:15 PM EST
VIA GLOBENEWSWIRE

$OncoCyte (OCX.US)$
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study
Wednesday, 4th December at 4:15 pm
IRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay.
In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling ...

$OncoCyte (OCX.US)$
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms
Monday, 2nd December at 4:05 pm
• Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population 
• Study shows that monitoring with Oncocyte's assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies 
• Early detection of transplant rejection is g...

$OncoCyte (OCX.US)$ Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms
2 MINUTES AGO, 4:05 PM EST
VIA GLOBENEWSWIRE
• Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population 
• Study shows that monitoring with Oncocyte's assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies 
• Early detection of transplant...

$OncoCyte (OCX.US)$ Top up

$OncoCyte (OCX.US)$ Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
9 MINUTES AGO, 6:35 PM EDT
VIA GLOBENEWSWIRE

$OncoCyte (OCX.US)$
Oncocyte Signs Leading Transplant Centers in US and Germany
Oncocyte (Nasdaq: OCX) has announced new agreements with two leading transplant university hospitals in the U.S. and Germany to utilize GraftAssure™, the company's research-use-only assay for detecting early evidence of graft organ damage. This development is part of Oncocyte's strategy to drive commercial adoption of its molecular diagnostic tests in the estimated $1 billion transplant addressable market.
...